Significant Changes in Medicaid Treatment Protocols and Medicare Payment Structures

The recent updates from the Health and Human Services Office of Inspector General and the Centers for Medicare & Medicaid Services (CMS) signal significant changes for healthcare providers, with implications for Medicaid treatment protocols and Medicare payment structures.

The Office of Inspector General (OIG) published a report on November 2, 2026, revealing that fewer than a quarter of Medicaid beneficiaries with hepatitis C received treatment within the recommended six-month period. Using data from 2023 and 2024, the treatment rate was a mere 23 percent. The low rates were especially prominent among individuals diagnosed with acute hepatitis C and those with dual eligibility. In response, OIG recommended CMS improve treatment access, a suggestion CMS fully endorses.

CMS followed with the unveiling of the Calendar Year 2027 Medicare Physician Fee Schedule on November 4, 2026, featuring a reduction in payment rates. Notably, the conversion factor for qualifying Alternative Payment Model (APM) participants decreased to $32.95, while non-qualifying participants saw a rate drop to $32.63. This reduction is part of broader rules, including restricted reimbursement for remote monitoring services to clinician employees and adjustments to the indirect practice cost index. The policy will also implement a reduced payment rate for concurrent surgical and evaluation services beginning January 1, 2027.

Upcoming Payment Adjustments and Policy Changes

Along with the Physician Fee Schedule, CMS introduced the CY 2027 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System rule, raising payments by 2.3 percent. This rule also implements site-neutral payment policies for off-campus departments and reduces drug reimbursements under the 340B Program.

For home health providers, payments will increase by 2.4 percent without affecting overall budget neutrality, thanks to strategic temporary reductions. This new rule expands CMS's ability to retroactively revoke provider enrollments starting January 1, 2027, signaling heightened regulatory oversight.

Key Points for Insurance Professionals

  • Medicaid hepatitis C treatment compliance needs improvement; CMS is urged to enhance treatment access.
  • Medicare Physician Fee Schedule cuts may financially impact service providers and require strategic adjustments.
  • Hospital and ASC reimbursement adjustments will modestly increase payments, impacting financial planning.
  • Home health payments rise slightly, but changes include potential retrospective provider enrollment revocations.
  • New drug price negotiation rules will start impacting pricing and contracts by 2029.
  • Proposed administrative cuts could save $320 million, reducing some operational burdens but may change compliance protocols.

Long-term Regulatory Impact

CMS's regulatory updates also unfold new drug price negotiation frameworks as part of the Medicare Drug Price Negotiation Program. These changes, set to take effect in 2029, are influenced by the Inflation Reduction Act, aiming for broader financial sustainability in healthcare programs.

In the quest for enhanced efficiency, CMS has introduced a proposal targeting the reduction of administrative burdens on healthcare providers. Expected to save an estimated $320 million, this move includes relaxed staff training requirements and streamlined reporting across various facilities. CMS seeks public comments on this effort, reflecting a continuous drive to balance regulatory oversight with operational efficiency.

These updates underscore CMS's commitment to refining healthcare delivery systems, balancing financial constraints with service excellence, and require keen observation by insurance professionals. Adjustments in payment models, treatment access, and operational processes will be crucial for navigating potential impacts on the insurance landscape. Providers and insurers must remain vigilant to adapt effectively to these evolving regulatory mandates.